Mabworks Biotech's Series B Round

Mabworks Biotech raised a round of funding on January 24, 2017.

Beijing Mabworks Biotech is a developer of gene engineering antibody medicines. Mabworks is currently developing antibody drugs, including an Ebola cure MIL77. Founded in 2003, Mabworks has two drugs …

Articles about Mabworks Biotech's Series B Round: